Biomea Fusion to Participate in Upcoming Investor Conferences

Biomea Fusion will meet investors and present at two New York conferences in September 2026, with a webcast available for one presentation.

Rhea-AI Summary

Biomea Fusion (BMEA) will participate in two investor conferences in September 2026 in New York. Management will attend Citi's 2026 Biopharma Back to School Conference for one-on-one investor meetings on September 10, 2026. The company will also present at the H.C. Wainwright 28th Annual Global Investment Conference at 11:00 a.m. ET on September 15, 2026, and hold additional one-on-one meetings. An audio webcast and replay of the H.C. Wainwright presentation will be available on Biomea’s website under Investors & Media.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences:

• Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
  
• H.C. Wainwright 28^th Annual Global Investment Conference: Biomea will present at 11:00 a.m. ET on September 15, 2026, in New York, NY. Management will also participate in one-on-one investor meetings during the conference.
  

An audio webcast of the presentation will be available on the News & Events page under the Investors & Media section of Biomea’s website. A replay of the webcast will be available following the presentation.

About Biomea Fusion  
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. 
 
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com

FAQ

When will Biomea Fusion (BMEA) attend Citi's 2026 Biopharma Back to School Conference?

Biomea Fusion will participate in one-on-one investor meetings at Citi's 2026 Biopharma Back to School Conference on September 10, 2026, in New York, NY.

What is the date and time of Biomea Fusion's presentation at the H.C. Wainwright 28th Annual Global Investment Conference?

Biomea Fusion will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 11:00 a.m. ET in New York, NY.

Will there be a webcast of Biomea Fusion's presentation at the H.C. Wainwright conference?

Yes. An audio webcast of Biomea Fusion's presentation at the H.C. Wainwright 28th Annual Global Investment Conference will be available on the News & Events page under the Investors & Media section of the company’s website, with a replay available after the presentation.

Is Biomea Fusion offering one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference?

Yes. Biomea Fusion's management will participate in one-on-one investor meetings during the H.C. Wainwright 28th Annual Global Investment Conference in addition to its formal presentation.

What type of company is Biomea Fusion (BMEA) as described in the conference announcement?

Biomea Fusion is described as a clinical-stage diabetes and obesity company, and members of its management team will use the upcoming September 2026 conferences for presentations and one-on-one investor meetings.